The TBXAS1 antibody targets thromboxane A synthase 1 (TBXAS1), an enzyme encoded by the TBXAS1 gene, which plays a critical role in the arachidonic acid metabolic pathway. TBXAS1 catalyzes the conversion of prostaglandin H2 (PGH2) to thromboxane A2 (TXA2), a potent mediator of platelet aggregation, vasoconstriction, and smooth muscle proliferation. Dysregulation of TBXAS1 activity or expression has been implicated in cardiovascular diseases, thrombotic disorders, and certain cancers, making it a focus of both basic and clinical research.
Antibodies against TBXAS1 are essential tools for studying its expression, localization, and function in various tissues and disease models. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), and ELISA to quantify protein levels or assess tissue-specific distribution. Researchers also employ TBXAS1 antibodies to investigate its role in pathological conditions, including atherosclerosis, hypertension, and tumor angiogenesis.
Commercial TBXAS1 antibodies are typically raised in hosts like rabbits or mice, with formats ranging from monoclonal to polyclonal. Specificity is validated using knockout cell lines or siRNA-mediated knockdowns to ensure minimal cross-reactivity. Recent studies highlight TBXAS1's potential as a therapeutic target, driving demand for high-quality antibodies in drug development and biomarker discovery. However, variability in antibody performance across applications necessitates careful validation for experimental reproducibility.